StreetInsider.com News Articles

Theralase(R) to Present at ThinkEquity Conference

Fri, 09 Oct 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 9, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of proprietary Energy-Activated Small Molecules ("EASMs") for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that the Company has been invited to present at the 2026 ThinkEquity Conference in New York.

ThinkEquity is a boutique investment bank that has collectively financed over $50 billion of public and private capital raises, restructurings, mergers and acquisitions. The annual ThinkEquity Conference brings together institutional investors, accredited investors and industry executives

Theralase(R) to Present at ThinkEquity Conference

Fri, 09 Oct 2026 07:00:00 -0400

Theralase(R) to Present at ThinkEquity Conference

Fri, 09 Oct 2026 07:00:00 -0400

Theralase(R) to Present at ThinkEquity Conference

Fri, 09 Oct 2026 07:00:00 -0400

Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements

Fri, 18 Sep 2026 07:00:00 -0400

Theralase^® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline

This Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)

Toronto, Ontario--(Newsfile Corp. - September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released its unaudited interim consolidated financial statements for the six-month period ended June 30th, 2026 ("Financial Statements").

Theralase® will be hosting a conference call on September 3^rd at

Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements

Fri, 18 Sep 2026 07:00:00 -0400

Theralase^® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline

This Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)

Theralase® will be hosting a conference call on September 3^rd at

Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements

Fri, 18 Sep 2026 07:00:00 -0400

Theralase^® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline

This Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)

Theralase® will be hosting a conference call on September 3^rd at

Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial Statements

Fri, 18 Sep 2026 07:00:00 -0400

Theralase^® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline

This Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)

Theralase® will be hosting a conference call on September 3^rd at

Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)

Tue, 15 Sep 2026 07:00:00 -0400

Successful completion of GLP toxicology analysis for the intravenous administration of Rutherrin(R) lays the groundwork for regulatory submissions supporting first-in-human clinical development for multiple life-threatening cancers

Toronto, Ontario--(Newsfile Corp. - September 15, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that Good Laboratory Practice ("GLP") toxicology analysis of intravenously administered Rutherrin® has commenced.

Rutherrin® is formed by combining Theralase®'s lead small molecule Ruvidar® with transferrin (blood plasma

Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)

Tue, 15 Sep 2026 07:00:00 -0400

Rutherrin® is formed by combining Theralase®'s lead small molecule Ruvidar® with transferrin (blood plasma

Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)

Tue, 15 Sep 2026 07:00:00 -0400

Rutherrin® is formed by combining Theralase®'s lead small molecule Ruvidar® with transferrin (blood plasma

Theralase(R) Commences GLP Toxicology Analysis of Rutherrin(R)

Tue, 15 Sep 2026 07:00:00 -0400

Rutherrin® is formed by combining Theralase®'s lead small molecule Ruvidar® with transferrin (blood plasma

Theralase(R) Releases Q2 2026 Financial Statements

Fri, 28 Aug 2026 16:36:00 -0400

Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline

Toronto, Ontario--(Newsfile Corp. - August 28, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of various cancers, bacteria and viruses, has released the Company's unaudited interim consolidated financial statements for the six-month period ended June 30th, 2026 ("Financial Statements").

Theralase® will be hosting a conference call on September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for

Theralase(R) Releases Q2 2026 Financial Statements

Fri, 28 Aug 2026 16:36:00 -0400

Theralase(R) Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology Pipeline

Theralase® will be hosting a conference call on September 3rd at 11:00 am ET, which will include a presentation of the financial and operational results for

Theralase(R) Closes C$3.6 Million Brokered Financing

Mon, 24 Aug 2026 17:01:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 24, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has closed its previously announced brokered private placement offering ("Offering"), pursuant to which the Company issued 14,812,500 units ("Units") at a price of C$0.24 per Unit ("Offering Price") for aggregate gross proceeds of C$3,555,000. The Offering was led by Research Capital Corporation as sole agent and sole bookrunner ("Agent").

Each Unit consists

Theralase(R) Closes C$3.6 Million Brokered Financing

Mon, 24 Aug 2026 17:01:00 -0400

Each Unit consists

Theralase(R) Announces $5 Million Brokered LIFE Offering

Mon, 10 Aug 2026 17:15:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Agent") to act as the sole agent and sole bookrunner on a commercially reasonable "best efforts" agency basis for a brokered private placement offering ("Offering") of units of the Company ("Units") at a price of C$0.24 per Unit, to

Theralase(R) Announces $5 Million Brokered LIFE Offering

Mon, 10 Aug 2026 17:15:00 -0400

Theralase(R) Grants Stock Options

Fri, 07 Aug 2026 17:25:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options.

The Company has granted an aggregate of 7,000,000 stock options to eligible participants pursuant to the Company's stock option plan. The options are exercisable at a price of C$0.265 per common share, vest over a three-year period and expire five years from the date of grant. The stock option grant is subject

Theralase(R) Grants Stock Options

Fri, 07 Aug 2026 17:25:00 -0400

Theralase(R) Engages Global One Media to Expand Global Investor Awareness

Tue, 04 Aug 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has engaged Global One Media Group Pte. Ltd. ("Global One Media") to provide digital investor marketing and communications services to the Company.

Global One Media is an arm's-length investor marketing firm headquartered in Singapore that specializes in digital investor communications for publicly traded companies. Its services include strategic messaging, video production, social

Theralase(R) Engages Global One Media to Expand Global Investor Awareness

Tue, 04 Aug 2026 07:00:00 -0400

Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

Tue, 30 Jun 2026 16:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 ("Prospectus") with the securities regulatory authorities in all provinces and territories of Canada.

The Prospectus will allow Theralase® to offer up to C$100 Million of common shares, warrants, subscription receipts, debt securities or any combination thereof

Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus

Tue, 30 Jun 2026 16:30:00 -0400

The Prospectus will allow Theralase® to offer up to C$100 Million of common shares, warrants, subscription receipts, debt securities or any combination thereof

Theralase(R) Lists Warrants on the TSXV

Wed, 03 Jun 2026 07:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 3, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that the TSX Venture Exchange ("TSXV") has accepted for listing up to 20,399,050 common share purchase warrants of the Company ("Warrants"), bearing the CUSIP: 88337V142, for trading on the TSXV. The Warrants are expected to commence trading on the TSXV at the open of markets on June 9^th, 2026, under the trading